A Phase 1 Study of the VEGF Receptor Tyrosine Kinase Inhibitor Axitinib (INLYTA, IND# TBD) in Children With Recurrent or Refractory Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 20 Nov 2017
At a glance
- Drugs Axitinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 13 Nov 2017 Planned End Date changed from 31 Oct 2017 to 1 Nov 2017.
- 20 Jun 2017 Status changed from completed to active, no longer recruiting.
- 05 May 2017 Status changed from active, no longer recruiting to completed.